Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Net Margin (2016 - 2025)

Amicus Therapeutics' Net Margin history spans 16 years, with the latest figure at 0.91% for Q4 2025.

  • For the quarter ending Q4 2025, Net Margin fell 893.0% year-over-year to 0.91%, compared with a TTM value of 4.27% through Dec 2025, up 635.0%, and an annual FY2025 reading of 4.27%, up 635.0% over the prior year.
  • Net Margin for Q4 2025 was 0.91% at Amicus Therapeutics, down from 10.24% in the prior quarter.
  • The five-year high for Net Margin was 10.24% in Q3 2025, with the low at 108.31% in Q1 2022.
  • Average Net Margin over 5 years is 42.48%, with a median of 42.3% recorded in 2022.
  • Year-over-year, Net Margin surged 4807bps in 2021 and then plummeted -1082bps in 2022.
  • Tracing FOLD's Net Margin over 5 years: stood at 101.37% in 2021, then surged by 37bps to 63.41% in 2022, then soared by 54bps to 29.41% in 2023, then surged by 133bps to 9.85% in 2024, then crashed by -91bps to 0.91% in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Net Margin are 0.91% (Q4 2025), 10.24% (Q3 2025), and 15.79% (Q2 2025).